摘要
目的分析在肥胖型2型糖尿病患者中采用利拉鲁肽联合二甲双胍治疗的效果及其对炎性因子水平的影响。方法便利选取2020年1月—2023年1月赤峰市肿瘤医院(赤峰学院第二附属医院)收治的82例肥胖型2型糖尿病患者为研究对象,按治疗方式分为对照组、观察组,各41例,分别予以二甲双胍治疗、二甲双胍+利拉鲁肽治疗。对比两组治疗效果、炎性因子、血糖及肥胖指标、不良反应发生情况。结果对照组治疗总有效率为80.49%(33/41),低于观察组的97.56%(40/41),差异有统计学意义(χ^(2)=4.493,P<0.05)。治疗3个月后,对照组C反应蛋白、白细胞介素6水平高于观察组,空腹血糖、餐后2 h血糖、糖化红蛋白水平均比观察组差,体脂百分比及内脏脂肪含量高于观察组,差异均有统计学意义(P均<0.05)。两组不良反应总发生率对比,差异无统计学意义(P>0.05)。结论合用利拉鲁肽、二甲双胍治疗肥胖型2型糖尿病患者具有一定优势,其不仅能够协同调控血糖水平,同时可有效促进体质量降低。
Objective To analyze the effect of liraglutide combined with metformin in obese patients with type 2 diabe⁃tes and its effect on the level of inflammatory factors.Methods A total of eightytwo obese patients with type 2 diabe⁃tes mellitus admitted to Chifeng Cancer Hospital(The Second Affiliated Hospital of Chifeng University)from January 2020 to January 2023 were conveniently selected as the research objects.According to the treatment methods,they were divided into control group and observation group,with fortyone cases in each group.They were treated with met⁃formin and metformin+liraglutide respectively.The therapeutic effect,inflammatory factors,blood glucose and obe⁃sity indexes and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the control group was 80.49%(33/41),which was lower than 97.56%(40/41)in the observation group,and the dif⁃ference was statistically significant(χ^(2)=4.493,P<0.05).After 3 months of treatment,the levels of Creactive protein and interleukin 6 in the control group were higher than those in the observation group,the levels of fasting blood glu⁃cose,2 h postprandial blood glucose and glycosylated red protein were worse than those in the observation group,and the body fat percentage and visceral fat content were higher than those in the observation group,the differences were statistically significant(all P<0.05).There was no significant difference in the total incidence of adverse reactions be⁃tween the two groups(P>0.05).Conclusion The combination of liraglutide and metformin has certain advantages in the treatment of obese patients with type 2 diabetes.It can not only synergistically regulate blood glucose levels,but also effectively promote weight loss.
作者
罗会东
曹瑾美
宋丽杰
LUO Huidong;CAO Jinmei;SONG Lijie(Department of Endocrinology,Section One,Chifeng Cancer Hospital(The Second Affiliated Hospital of Chifeng University),Chifeng 024000,Inner Mongolia Autonomous Region,China)
出处
《系统医学》
2025年第11期111-114,共4页
Systems Medicine
关键词
2型糖尿病
肥胖患者
利拉鲁肽
二甲双胍
治疗效果
炎性因子
Type 2 diabetes
Obese patients
Liraglutide
Metformin
Treatment effect
Inflammatory factors
